Clinical Trial Update: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial investigating Immuncell-LC in combination with gemcitabine for resectable pancreatic ductal adenocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Immuncell-LC

Snippet

Sponsor: GC Cell Corporation | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 3 | Status: RECRUITING